<DOC>
	<DOC>NCT01540864</DOC>
	<brief_summary>The purpose of this study is to compare the safety and effect of HPP404 versus placebo on body weight in overweight or obese subjects.</brief_summary>
	<brief_title>A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<criteria>Body Mass Index (BMI) from 30.0 to 39.9 kg/m2, for subjects with no additional co morbidities; BMI from 27 to 39.9 kg/m2, for subjects with co morbidities (i.e. dyslipidemia defined as high LDL (≥ 160 mg/dL) or high total cholesterol (≥ 240 mg/dL), or subjects with hypertension) Systolic blood pressure &gt; 160 mmHg and/or diastolic pressure &gt; 90 mmHg at the Screening Visit without treatment History of use of tobacco or nicotinecontaining products 180 days prior to Screening visit Subjects with type 2 diabetes or fasting blood glucose concentration ≥ 126 mg/dL History of appetite or weight modifying surgeries/procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Overweight</keyword>
	<keyword>Body Mass Index</keyword>
</DOC>